SecBot SecBot

JUNS

JUPITER NEUROSCIENCES, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001679628 Biotech & Drug Discovery
$2.86 −0.12 (−4.03%)
Oct 26 4:00 PM ET · prev $2.98
Market cap
$3.4M
Nano cap
1 year
−97.8%
from $127.50 · Oct 27
30 days
+13.9%
from $2.51
52-week range
$2.42–127.50
−98% from high · low Oct 5
Avg volume 20D
66.9K
Oct 6 spike 924.1K
Short interest
35.4K
≈2.7% of shares · −32.5%
Days to cover
1.0
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
14
analyzed by SecBot
SecBot read BEARISH 7 reports · 90 days
Balance 6 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 7/7
Strongest BEARISH Jupiter Neurosciences received a delisting notice from Nasdaq on August 27, 2026, for failing to maintain…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 0 added (0 new), 1 trimmed or exited.

  • Short sellersCOVERING

    Short interest −32.5% to 35.4K shares. 1.0 days to cover, ≈2.7% of shares.

  • TrendRANGE

    15% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
GEODE CAPITAL MANAGEMENT, LLCTRIM156,127$33.4K
GEODE CAPITAL MANAGEMENT, LLCADD211,696$79.6K
GEODE CAPITAL MANAGEMENT, LLCADD132,641$135.3K
UBS Group AGNEAR_EXIT4,090$7.2K
UBS Group AGTRIM53,916$55.0K
CITIGROUP INCNEAR_EXIT11,106$11.3K
UBS Group AGDOUBLED135,640$82.7K
CITIGROUP INCDOUBLED111,977$68.3K

Quarterly 13F filings are due 45 days after each quarter ends.

Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Aug 21, 2026
Trading halt
Halt Resumed: JUNS — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-08-21T16:45:32.000Z | Resumed 2026-08-21T16:50:32.000Z
Aug 21, 2026
Trading halt
Trading Halt: JUNS — LUDP (Volatility Trading Pause)
Jupiter Neurosciences Cmn | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Aug 21, 2026
Trading halt
Halt Resumed: JUNS — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-08-21T16:20:16.000Z | Resumed 2026-08-21T16:45:17.000Z
Aug 21, 2026
Trading halt
Trading Halt: JUNS — LUDP (Volatility Trading Pause)
Jupiter Neurosciences Cmn | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Aug 21, 2026
Press release
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
New York, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage…

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jul 31, 2026
Cutler Andrew Jon
Director
AWARD472,222 sh
Jun 29, 2026
Philipson Tomas Jan
Director
AWARD536,428 sh
Jun 2, 2026
Rosen Alexander Gustaf Erik
Chief Administrative Officer
AWARD341,843 sh
Jun 2, 2026
Weis Holger
Director
AWARD100,000 sh
Jun 2, 2026
Hemmerly Nicholas H.
Director
AWARD100,000 sh
Jun 2, 2026
ROSEN CHRISTER
CEO and Chairman
AWARD747,783 sh
Jun 2, 2026
Elmasri Saleem
Chief Financial Officer
AWARD525,565 sh
Jun 2, 2026
Kampf Julie B.
Director
AWARD100,000 sh

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Sep 30, 2026
35,426
shares short
-32.5%
vs prior settlement
1.0
days to cover
≈2.7%
of shares outstanding
Trading halts
Aug 21, 2026Volatility PauseResumed
Aug 21, 2026Volatility PauseResumed
Aug 21, 2026Volatility PauseResumed
Aug 6, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 24, 2026 SEC
Jupiter Neurosciences filed an S-3 registration statement to register 132,867 shares of common stock for resale by…
S-3 — Impact 5/10
Sep 22, 2026 SEC
PharmAla Biotech Holdings Inc. disclosed a 17.3% passive stake in Jupiter Neurosciences via a Schedule 13G filed…
SC 13G — Impact 4/10
Aug 28, 2026 SEC
Jupiter Neurosciences received a delisting notice from Nasdaq on August 27, 2026, for failing to maintain the minimum…
8-K — Impact 8/10
Aug 21, 2026 Trading halt
Halt Resumed: JUNS — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-08-21T16:45:32.000Z | Resumed 2026-08-21T16:50:32.000Z
Jul 31, 2026 Insider
Cutler Andrew Jon was granted 472,222 shares
Director
Jul 21, 2026 Press
Jupiter Neurosciences licensed exclusive U.S. rights to ALA-002, an FDA-designated Novel Chemical Entity (non-racemic…
Impact 7/10
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — TRIM
156,127 shares ($33.4K)
Jun 29, 2026 Insider
Philipson Tomas Jan was granted 536,428 shares
Director

SecBot reports

14 filings · 1 press release · 0 bullish · 10 bearish · 4 neutral
All JUNS filing & press-release reports (15)